A University of Houston pharmaceutical scientist is developing a new drug which could bring relief to children suffering with Familial Adenomatous Polyposis (FAP), a rare genetic disorder characterized by hundreds – if not thousands – of colorectal polyps. This hereditary cancer predisposition syndrome occurs in 3-per-100,000 live births and, if left untreated, causes colorectal cancer in patients nearly 100 percent of the time. Prior medication for the disease failed because it increased the risk of heart attacks and death.
“If successful, this drug will likely become the first drug for treating children with FAP and will also be useful for colon cancer prevention in other high-risk populations,” said Ming Hu, professor of pharmaceutics, who is using a $200,000 grant from the Cancer Prevention Research Institute of Texas (CPRIT) for a pilot study of the new drug’s effectiveness. Hu’s research team includes Greg Cuny, UH associate professor of medicinal chemistry, and Jason Eriksen, UH associate professor of pharmacology.
Children with FAP have to undergo routine colonoscopy and surgery (removal of polyps and intestinal segments) until the whole colon is eventually removed via colectomy. “The quality of life for children with FAP remains very poor,” said Hu.
Untreated, the disease causes growth of an out-of-control number of polyps that will progress to malignancy. For those who are undiagnosed by age 20, Ming says their life will probably end by 35, because the polyps will become numerous and malignant, leading to severe hemorrhage and deadly metastatic cancer.
To make matters worse, the Food and Drug Administration, which earlier approved the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib to treat FAP, had the FAP indication withdrawn because of the drug’s sometimes fatal toxicity to the heart. Scientists attribute the drug’s toxicity to the fact that it spreads throughout the body, rather than targeting only the affected organs.
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drugs, many of which have the same non-targeted organ toxicities. To call attention to these severe side effects, the FDA has ordered a “black box” warning be printed on the drug’s package to mark this life-threatening risk. As a result, children with FAP are left with no drugs for treatment.
Hu and his team took this opportunity to develop a more effective treatment through a locally bioavailable COX-2 inhibitor, meaning one that will remain inside the gut area. The new drug is designed to cycle through the colon without escaping to the circulatory system and reaching non-targeted organs. The drug inhibits the production of the molecule called PGE2, which magnifies pain and promotes tumor growth in the colon.
Hu says the drug will also be effective for preventing recurrence after the polyps are removed, which could lead to fewer incidents of colon cancer in high-risk populations.
“Nobody has designed a drug like this, which recycles and limits exposure to the target organ,” said Hu. He has filed a patent on this approach to designing drugs. “If this drug could help save patients and improve their quality of life, it would be a dream come true.”
When William’s cardiologist recommended a pacemaker, he was concerned his active lifestyle would slow. But thanks to a new type of pacemaker, he quickly adjusted. Read more: https://t.co/l3xLKKC8dx. https://t.co/0dL8nZ11Ay
#Melanoma survivor Steve Hamilton shares why he joined a clinical trial after melanoma spread: https://t.co/k9osfgANcm #CancerMoonshot #melsm #endcancer
RT @OPreventzaMD: Micaela,Thank you for allowing me to be part of your journey ! The Heart of Micaela's Fondest Wish https://t.co/lFYWiyIWS…
Air Force Veteran Receives Award for Excellence in Prosthodontics https://t.co/dUekng0ETf via @PRNews
RT @BCMHouston_News: A cold can make you feel miserable for days. How can we avoid catching a cold, or even prevent one from developing? @b…
Spice up your week with this delicious chickpea curry recipe from @CHEFSanAntonio. https://t.co/L5qxm7E9tD
This week, patients and visitors can find a our holiday coffee carts out and about serving festive beverages. Thanks to our volunteers for helping to spread cheer. #endcancer https://t.co/J6wYRpp2aA
Here's why it's a bad idea for students to use energy drinks to help cram for exams: https://t.co/9F0um9sxnO
A @UTHealth large-scale review study on misleading medical videos was cited in this @Forbes story about why using #socialmedia for medical information is not a good idea: https://t.co/3Q533OwwEF
Tune in to @KPRC2 tonight at 10 p.m. to hear about meteorologist Frank Billingsley's journey with #ProstateCancer, his participation in UTHealth's innovative research with a @UTPhysicians doctor, and the results! https://t.co/yvpF7DDxfE #ManyFacesOfUTHealth
#OperationSong – “He Took My Place” by Gary Lima https://t.co/SlxZvipXYY via #VAntagePoint
RT @wishnj: Micaela has always dreamed of becoming a cardiothoracic surgeon. Her fondest wish came true when she traveled to the @Texas_Hea…
University of Houston@UHouston
RT @uhit: Attn #Coogs! Before you leave for the break, log into AccessUH to see when your CougarNet password expires so it'll be ready to…
Congrats to our P10 Nursing unit for winning our annual Holiday Tree Decorating Contest with their superhero-themed tree.Thanks to our employees who participated. You all deserve an award for bringing joy to our patients and caregivers this holiday season. #endcancer https://t.co/kK8TByXehe
CHI St. Luke's Health@CHI_StLukes
RT @sfoster23: So proud of @CHI_StLukes Patients Medical Center staff for supporting our Catholic Health Initiatives core values on Sunday…